APITOPE FREE DOWNLOAD

New Tech drives pharmaceutical automation and manufacturing. Symptoms can include an enlargement of the thyroid gland, swelling of the neck, localised abnormalities of skin, tremors, heat intolerance and sweating, significant weight loss, osteoporosis, atrial fibrillation and ocular changes in patients. The current scenario in Pharmaceutical Packaging Development. Autoimmune diseases are typically treated with therapies that globally suppress the immune system. The fact the company is willing to merge with complementary Flemish science and activities strengthens our belief in the future success of Apitope. I look forward to maximis ing the potential of these important new treatments and lead the Company through its next phase of growth.

Uploader:	Kigazragore
Date Added:	6 June 2012
File Size:	53.66 Mb
Operating Systems:	Windows NT/2000/XP/2003/2003/7/8/10 MacOS 10/X
Downloads:	74247
Price:	Free* [*Free Regsitration Required]

Apitope preps Graves’ disease drug for phase 2 after positive trial | FierceBiotech

Submitted by vesalius on March 29, - The current scenario in Pharmaceutical Packaging Development. He will remain on the Apitope Board as a non-executive director.

Wednesday, March 27, Such therapies address the symptoms of the disease, not the cause, and increase the risk to life-threatening infections, cancers and other immune complications. Process Validation, the Bedrock of Success.

By continuing to use this site you consent to the use of cookies, apittope disabled from your browser.

Treatments for autoimmune diseases represent a large and apihope industry that has been gaining momentum, with five out of ten best selling drugs in targeting autoimmune diseases [4].

S he has played a major role in Apitope ' s growth and success over the past eight years and the Board is confident in her expertise and experience in progressing Apitope ' s growth and maximising the potential of its clinical programmes.

Apitope Announces Management Changes | Markets Insider

The Regenerative Medicine Supply Chain. Apitope, a clinical stage biotech company developing potential first-in-class antigen-specific immunotherapies targeting autoimmune diseases, today announces that Chief Executive Officer CEO Dr Keith Martin has decided to retire from the CEO role after 12 years at the helm of Apitope.

Nico Vandervelpen and Dr. Rising demand for stability studies. The investigational product was administered intradermally ID every two weeks over a period of 18 weeks in male and female patients that were not otherwise being treated with anti-thyroid therapy. Tuesday, May 7, New Tech drives pharmaceutical automation and manufacturing. Other supervisory board members are Dr. N Engl J Med. Dr French started her career at University College London Ventures where she was responsible for the development, management and commercialisation of technologies in the life sciences sector.

Velesco Pharma set for clinical manufacturing capacity expansion.

Symptoms can include an enlargement of the thyroid gland, swelling of the neck, localised abnormalities of skin, tremors, heat intolerance and sweating, significant weight loss, osteoporosis, aitope fibrillation and ocular changes in patients. Home Magazine Event Videos Gallery.

Apitope Announces Management Changes

Office of Women's Health US 2. Registration on or use of this site constitutes acceptance of our Terms of ServiceCookie Policyand Privacy Policy. Under his strategic leadership Apitope has grown to be a clinical stage biotech with multiple program me s in development for diseases with high unmet needs.

USV to invest Rs million in a new plant in…. Sygnature Discovery develops AR molecular visualisation prototype. Vesalius Biocapital offers venture capital to young European innovative life science companies. Innovator Capital, the Londonbased investment bank, advised on and managed the capital raising for Apitope. Piet Stinissen and Prof. In addition, Apitope has an innovative pipeline with several potential first-in-class candidates advancing towards clinical development.

The fact the company is willing to merge with complementary Appitope science and activities strengthens our aputope in the future success of Apitope.

PCI unveils expanded clinical services center in Rockford. O n behalf of the Board we would like to thank Keith for his contribution to Apitope and we are delighted he will stay on the Board as a Non-executive Director.

Apitope International NV, the developer of novel peptide-based therapies for autoimmune diseases and allergies, today announced the closing of a EUR 10 million series A financing. An autoimmune disease occurs when the immune system mounts an undesired response to an innocuous self-antigen and attacks healthy tissues in the body.